OnKure Therapeutics
OKUR
68 hedge funds and large institutions have $40.6M invested in OnKure Therapeutics in 2023 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 17 closing their positions.
197% more call options, than puts
Call options by funds: $3.38M | Put options by funds: $1.14M
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
17% more funds holding
Funds holding: 58 → 68 (+10)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0.47% less ownership
Funds ownership: 8.09% → 7.63% (-0.47%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
80% less capital invested
Capital invested by funds: $208M → $40.6M (-$168M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$20.8M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$8.19M |
| 3 |
HCM
Highbridge Capital Management
New York
|
+$6.99M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.63M |
| 5 |
BlackRock
New York
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$25.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$15.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$11.4M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.89M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$3.43M |
OKUR Hedge Fund Activity: Q4 2023 in Review
68 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q4 2023, worth a combined $40.6M — down 80% from $208M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new OKUR positions and 17 closed out — a net gain of 10 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $20.8M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $25.3M sold.
- 68 institutional investors held OnKure Therapeutics (OKUR) as of Q4 2023, up from 58 in Q3 2023.
- Funds reported $40.6M of OnKure Therapeutics stock for Q4 2023, down 80% quarter-over-quarter.
- 27 funds opened new OnKure Therapeutics positions in Q4 2023 and 17 closed out, a net change of +10 holders.
- The largest OnKure Therapeutics buyer in Q4 2023 was Tang Capital Management, an estimated $20.8M added.
- The largest OnKure Therapeutics seller in Q4 2023 was Novo Holdings A/S, an estimated $25.3M sold.
Based on aggregated 13F filings for Q4 2023.